A Tumor Marker Panel Scoring System To Improve Clinical Stage In Gastric Cancer

Jun Gong,Jiu-Yang Liu,Chun-Wei Peng,Yang Yu,Xiao-Hua Leng,Cong-Hua Xie,Yan Li
2016-01-01
Abstract:Objective: To investigate the correlation among tumor markers test/reference cutoff ratio score (TRRS), disease progression and clinical stages in gastric cancer (GC). Methods: 708 patients hospitalized because of GC for the first time with preoperative tumor makers [carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, and CA125] measured between January 2005 and December 2014 at Zhongnan Hospital of Wuhan University were enrolled. We analyzed the relationship among tumor makers, disease progression and clinical stages, retrospectively. Results: CEA, CA19-9 and CA125 test/reference cutoff ratio (TRR) levels were increased significantly according to the clinical stages, TRRS were significantly correlated with the depth of tumor invasion, lymph node metastasis, distant metastasis and clinical stage (All P < 0.001). A tumor marker panel scoring system (TMSS) was devised as we defined Negative TMSS (TMSS = 0), Low TMSS (1 = TMSS = 3), Middle TMSS (4 = TMSS = 6), High TMSS (7 = TMSS = 9) based on the calculated TRR score. TMSS was significantly correlated with clinical stage. The later the TNM stage was, the higher the percentage of Middle and High TMSS will became. The distribution of TMSS in GC patients with High TMSS was found in advanced stages (stage III and IV). Conclusions: CEA, CA19-9 and CA125 TRRS are useful indicators for disease progression in GC patients hospitalized for the first time, the TMSS could be a useful tool for the prediction of clinical stage, especially for the advanced stage.
What problem does this paper attempt to address?